相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trabectedin for advanced soft tissue sarcomas: a single institution experience
Ioannis Gounaris et al.
FUTURE ONCOLOGY (2014)
Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma
Jean Yves Blay et al.
FUTURE ONCOLOGY (2014)
Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma
Takafumi Ueda et al.
INVESTIGATIONAL NEW DRUGS (2014)
Mode of action of trabectedin in myxoid liposarcomas
S. Di Giandomenico et al.
ONCOGENE (2014)
Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study
B. L. Samuels et al.
ANNALS OF ONCOLOGY (2013)
Trabectedin in patients with metastatic soft tissue sarcoma: a retrospective single center analysis
Sophie Schur et al.
ANTI-CANCER DRUGS (2013)
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
Jean-Yves Blay et al.
BMC CANCER (2013)
Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin
Sabino Strippoli et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2013)
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
A. L. Cesne et al.
BRITISH JOURNAL OF CANCER (2013)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin
Daniela D'Angelo et al.
EUROPEAN JOURNAL OF CANCER (2013)
Safety evaluation of trabectedin in treatment of soft-tissue sarcomas
Juan Martin-Liberal et al.
EXPERT OPINION ON DRUG SAFETY (2013)
The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS)
F. Ploner et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
A. Gronchi et al.
ANNALS OF ONCOLOGY (2012)
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
L. C. Hanker et al.
ANNALS OF ONCOLOGY (2012)
Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies
R. Thertulien et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
Federica Grosso et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment
P. Allavena et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2012)
Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Bradley J. Monk et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
Luis Paz-Ares et al.
INVESTIGATIONAL NEW DRUGS (2012)
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
Axel Le Cesne et al.
INVESTIGATIONAL NEW DRUGS (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance
Ioana Abraham et al.
MARINE DRUGS (2012)
Prolonged Disease Stability With Trabectedin in a Heavily Pretreated Elderly Patient With Metastatic Leiomyosarcoma of the Thigh and Renal Failure: A Case Report and Review of the Literature
Danilo Galizia et al.
ONCOLOGY RESEARCH (2012)
Administration of 24-h Intravenous Infusions of Trabectedin in Ambulatory Patients with Mesenchymal Tumors via Disposable Elastomeric Pumps: An Effective and Patient-Friendly Palliative Treatment Option
Patrick Schoeffski et al.
ONKOLOGIE (2012)
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis
Claudia Lebedinsky et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease
Juliette Thariat et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Clinical Trials in Recurrent Ovarian Cancer
Michael Friedlander et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing
Francoise Ducimetiere et al.
PLOS ONE (2011)
Trabectedin: Safety and Efficacy in the Treatment of Advanced Sarcoma
Csaba Gajdos et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2011)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
N. Colombo et al.
ANNALS OF ONCOLOGY (2010)
Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2010)
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Giovanni Germano et al.
CANCER RESEARCH (2010)
Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors
Quincy Chu et al.
CLINICAL CANCER RESEARCH (2010)
Trabectedin therapy for sarcomas
Paolo G. Casali et al.
CURRENT OPINION IN ONCOLOGY (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Review of Trabectedin (ET-743): A Unique Mechanism of Action
Maurizio D'Incalci et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
J. M. Del Campo et al.
ANNALS OF ONCOLOGY (2009)
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series
F. Grosso et al.
ANNALS OF ONCOLOGY (2009)
Phase I clinical and pharmacokinetic study of trablectedin and cisplatin in solid tumours
C. Sessa et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer
C. Sessa et al.
EUROPEAN JOURNAL OF CANCER (2009)
Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer From Platinum Doublets to Nonplatinum Doublets and Adding Antiangiogenesis Compounds
Bradley J. Monk et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Recognition of a New Chemotherapeutic Vesicant: Trabectedin (Ecteinascidin-743) Extravasation With Skin and Soft Tissue Damage
Todd A. Theman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
MAPPING THE LITERATURE: ROLE OF TRABECTEDIN AS A NEW CHEMOTHERAPY OPTION IN ADVANCED PRETREATED SOFT TISSUE SARCOMA
A. Le Cesne et al.
DRUGS OF TODAY (2009)
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
M. von Mehren et al.
ANNALS OF ONCOLOGY (2008)
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
Wells A. Messersmith et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
Jean-Yves Blay et al.
CLINICAL CANCER RESEARCH (2008)
Role of homologous recombination in trabectedin-induced DNA damage
M. Tavecchio et al.
EUROPEAN JOURNAL OF CANCER (2008)
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
Martee L. Hensley et al.
GYNECOLOGIC ONCOLOGY (2008)
Second-line randomized trials in epithelial ovarian cancer
J. B. Vermorken
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity
Jin Kyung Lee et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2008)
Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis
C. Bosetti et al.
ANNALS OF ONCOLOGY (2008)
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas
Robert G. Maki et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Federica Grosso et al.
LANCET ONCOLOGY (2007)
Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer
Jan H. Beumer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis (R)) in cancer patients
Juan Jose Perez-Ruixo et al.
CLINICAL PHARMACOKINETICS (2007)
Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin
Ana B. Herrero et al.
CANCER RESEARCH (2006)
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma
F. Grosso et al.
EUROPEAN JOURNAL OF CANCER (2006)
ET-743:: a novel agent with activity in soft-tissue sarcomas
Jerome Fayette et al.
CURRENT OPINION IN ONCOLOGY (2006)
In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line:: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction
EFA Brandon et al.
ANTI-CANCER DRUGS (2005)
Trabectedin (Yondelis™, formerly ET-743), a mass balance study in patients with advanced cancer
JH Beumer et al.
INVESTIGATIONAL NEW DRUGS (2005)
Medical progress: Soft-tissue sarcomas in adults
MA Clark et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Hepatotoxicity and metabolism of trabectedin: a literature review
JH Beumer et al.
PHARMACOLOGICAL RESEARCH (2005)
Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): Inhibition of macrophage differentiation and cytokine production
P Allavena et al.
CANCER RESEARCH (2005)
Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
A Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
R Garcia-Carbonero et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
A Yovine et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity
TA Puchalski et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Thyroid cell transformation requires the expression of the HMGA1 proteins
MT Berlingieri et al.
ONCOGENE (2002)
Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias
S Scala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study
O Merimsky et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
分享论文
